On July 23, CME Group Inc rose 3.26% in regular trading, trading at $256.45/share, with turnover of $150 million.

On the news front, following the company's Q2 earnings beat released the prior session, multiple investment banks raised their target prices. Goldman Sachs lifted its target from $243 to $252, while Morgan Stanley raised its target from $324 to $330. The analyst consensus maintains an overweight rating with a mean target price of $284.20.

The Q2 results showed adjusted EPS of $2.99, exceeding the $2.91 consensus estimate, while revenue of $1.706 billion topped the $1.685 billion expectation. Net income rose to approximately $1.042 billion. Performance was driven by heightened equity market volatility boosting hedging demand, with Q2 derivatives average daily volume reaching 29.8 million contracts — the second-highest level on record — and June ADV surging 19% year-over-year to a monthly record. Notably, multiple banks had cut target prices ahead of earnings, and the beat effectively reversed bearish sentiment, sustaining the stock's recovery trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)